BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 29, 2000
View Archived Issues
Extensive review of novel cytoprotectant appears in supplementary issue of DOT
Read More
NCI initiates third phase II trial of O6-benzylguanine in combination with BCNU
Read More
Pharming and Baxter to jointly develop treatment for hereditary angioedema
Read More
Carrington Laboratories discontinues development of Aliminase due to disappointing phase III results
Read More
Incyte Pharmaceuticals to change name to Incyte Genomics
Read More
Merck & Co. confirms study results of Singulair as allergic rhinitis treatment
Read More
Oxford BioMedica enters agreement with Nycomed Amersham for tumor imaging
Read More
Novel CRF antagonists under study at DuPont
Read More
3-Dimensional Pharmaceuticals begins clinical testing of oral thrombin inhibitor
Read More
New metabotropic glutamate receptor agonists for psychiatric, neurological disorders
Read More
Positive preliminary results reported for Enzo's phase I trial of EHT-899
Read More
UCB's new muscarinic agents useful for pain, schizophrenia and Alzheimer's disease
Read More
New series from SB interacts with signal transduction to inhibit inflammation
Read More
Novel gastric antisecretory agents designed by AstraZeneca scientists
Read More
Kinetek validates ILK inhibition as potential cancer therapy
Read More
BMS patents new antibacterial series useful against resistant infections
Read More
Highly potent and orally bioavailable nonbenzamidine factor Xa inhibitors presented to ACS
Read More
Cangene begins pivotal HBV study, terminates agreement with Octapharma
Read More
ACS news: BMS presents potent new inhibitor of cyclin-dependent kinases
Read More
SR-10204 and SR-10208 identified as potent anti-HCMV agents
Read More
Discovery of ischemia-selective NMDA antagonists reported at ACS by Cambridge NeuroScience
Read More
Salix receives FDA approvable letter for balsalazide disodium
Read More
Two studies presented in Yokohama explore effects of GA-0113 in pulmonary hypertension
Read More
The FDA approves Zonegran for the treatment of epilepsy
Read More
TRK-820 demonstrates kappa-receptor-mediated antipruritic effects in animal model
Read More
FK-960, a novel antidementia agent in phase II, increases synapse density in aged rats
Read More
New farnesyltransferase inhibitor L-779575 presented by Merck this week
Read More
R.W. Johnson presents R&D on nicotinic acetylcholine receptor ligands
Read More